Tag: Biologics
Potential biomarker discovered for treatment response to ustekinumab
TNF inhibitor for immune-mediated inflammatory disease doubles the risk of paradoxical psoriasis
Secukinumab also tolerable in paediatric psoriasis patients
The Yin and Yang of opposing vectors: an explanation for side effects of biologics
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Tapering biologics: No alarming signs of increased anti-drug antibodies
Existing and upcoming small molecules in psoriasis
Ixekizumab superior to secukinumab in real-world psoriasis study
Nail psoriasis: An important target to be treated
COVID-19 in patients with rheumatic disease: most report mild disease
Poor disease control: a risk factor for severe COVID-19
No heightened outcome risk for rheumatic patients with COVID-19
Real-world data on brodalumab affirms efficacy and fast onset of action
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Predicting individual effectiveness of biologics in severe asthma
Secukinumab monotherapy as efficient as adalimumab
AxSpA real-life remission rates higher on biologics
Biologics in HS – a growing armamentarium
Psoriasis therapy for children and pregnancies
Biologic psoriasis treatment to lower cardiovascular risk?
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Anifrolumab succeeds in second phase 3 trial in SLE
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
Biologics show similar activity in patients with elderly-onset RA
Biologics: increasingly used in paediatric dermatology
Novel treatment options for many dermatologic indications
Choosing the right biologic in psoriasis
Biologicals beyond TNF blockade
Registries – an important research tool in biologics
Advances in target-oriented therapy: psoriatic arthritis
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Small molecules, apremilast, and TYK2
Psoriasis and Biologics: The Beat Goes On
